* Kezar Life Sciences Inc is expected to show a fall in quarterly revenue when it reports results on November 13 (estimated) for the period ending January 1 0001
* The South San Francisco California-based company is expected to report a 88.6% decrease in revenue to $800 thousand from $7 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $3.15 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Kezar Life Sciences Inc is $25.00, above its last closing price of $7.37.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -3.39 -3.20 -2.70 Beat 15.7
Jan. 1 2024 -3.33 -3.33 -3.00 Beat 9.9
Dec. 31 2023 -4.30 -3.80 -4.40 Missed -15.8
Sep. 30 2023 -3.58 -3.49 -3.20 Beat 8.4
Jan. -3.21 -3.20 -3.40 Missed -6.2
1 0001
Mar. 31 2023 -2.90 -2.88 -3.10 Missed -7.5
Dec. 31 2022 -2.76 -2.50 Beat 9.6
Sep. 30 2022 -2.71 -2.70 -2.50 Beat 7.5
This summary was machine generated November 11 at 15:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments